Doubt about ketamine therapy usually arrives as a specific sentence. Someone heard something, repeated it, and now it sits in your head as fact. Here are six of those sentences, checked honestly, including the ones that turn out to be partly right.
Why bother? In a poll of 443 adults from ten Midwest states that we commissioned, a negative reaction to ketamine or esketamine therapy came from just 9 percent. Skeptics were 21 percent, the cautious but open 34, the hopeful or curious 18, and 18 percent had never heard of the idea. Half the room leans open and a small share is hostile, which suggests most doubt here is inherited rather than firmly held. The figures are final, after panel validation.
"It is a horse tranquilizer"
Partly true and misleading. Animal doctors do use ketamine, but so have human surgeons and emergency teams for decades, children included. The veterinary fact holds. The implication, that it was made for animals and repurposed by opportunists, does not.
The phrase lets you skip the real question: does a specific product, at a specific dose, in a specific setting, have evidence and approval behind it? That question has an answer, and it differs from clinic to clinic.
"None of this is FDA-approved"
False as stated, and true enough to keep asking about. Esketamine, marketed as Spravato, has FDA approval for depression that earlier medications failed to relieve, and nobody takes it outside a certified site's supervised room. That is an approved product with an approved use.
IV ketamine for depression is different. Clinicians use it off label, prescribing an approved drug for a purpose regulators never reviewed, which is legal and common but not the same thing. Compounded ketamine mailed home after a video appointment sits farther out still.
The corrected sentence: one version is approved, the others are not, and marketing rarely separates them. In our survey, 59 percent called FDA approval decisive or a big factor, so most people already want to apply this filter; they just lack the facts to do it. Brain Recovery Centers, which offers the approved spray, lays out what its Spravato treatment involves, which is one way to see the approved version in practice.
"It is the same thing people take at parties"
Same molecule, unrelated circumstances. Recreational use means unknown material, unknown dose, no screening, no monitoring, and no one checking your blood pressure. Clinical use means a measured dose, a licensed setting, and observation afterward for effects that are expected, not accidental.
The comparison also hides a real concern that deserves respect: ketamine has recognized misuse potential. That is no myth. It is one reason the approved product stays in certified settings instead of being sold as a take-home supply, and a reason to be more wary of home delivery, not less.
"Insurance never pays for it"
Too absolute, and the exceptions are the whole story. Coverage depends on the product, the diagnosis, the plan, and whether treatment-resistant depression is documented. The approved esketamine route is the one with any path through insurance; cash-pay infusion clinics and mail-order programs generally are not built for it. Do not take a promise from a website, ours included. Get a written benefits determination against your own member ID first.
Missourians in our sample seem willing to do the paperwork. Insurance weighed decisively or heavily for 65 percent. Offered a choice, half picked coverage with more hoops, while the rest divided between paying for speed (23 percent) and not knowing (26 percent). And the payer mix is not what a typical clinic plans for: commercial coverage at 39 percent and Medicaid at 37 were nearly tied, with Medicare at 23, and small slices for the uninsured (9) and TRICARE (5).
"If it worked, my doctor would have mentioned it"
Understandable, and weaker than it sounds. Awareness is thin everywhere in this conversation. Among our respondents, Spravato registered with almost no one: 73 percent had no recognition, 21 percent knew it as a name only, and 6 percent could say what it was.
Silence in a fifteen-minute appointment is not a clinical verdict; often it is just silence. Ask instead of inferring, which is what the sample said it would do: the primary doctor came first for 56 percent, and their own doctor's advice outweighed everything else at 74 percent, against 2 percent for advertising.
No recommendation is not a recommendation against. Ask out loud and you get an answer instead of a guess.
"It is a miracle cure, so it must be a scam"
The premise is the problem. Nobody honest claims a miracle. A clinic that promises you a result, quotes a success figure with no source, or offers relief to everyone has told you something about itself. It does not work for everyone, no response can be promised, and a serious program will say in advance how it will decide the treatment is not helping. Judge the specific offer, not the category's worst advertising.
Why any of this pressure exists
Because the standard route already failed a lot of households. When we asked, 72 percent of respondents said depression, anxiety, or PTSD had outlasted ordinary medication for themselves or for a loved one: 37 percent themselves and 22 percent a person close by, with 13 percent in both groups and 28 percent in neither. That is the demand under the ads, and it is why careless claims here do real harm.
Limits and one number that matters more
This is consumer research about beliefs, not clinical evidence, and none of it is medical advice or a recommendation. Your history decides whether any treatment suits you, and a clinician who can review it should make that call.
If what you are actually carrying is the thought that you would rather not be here, please set this page down. From any phone in the U.S., dialing or texting 988 puts you in touch with the Lifeline at any hour, at no cost, with nothing asked of you afterward. That conversation is available today.
Methodology
The percentages come from one first-party study the publisher commissioned and paid for, Pollfish consumer panel survey 395586438. Fieldwork closed June 23, 2026. Pollfish collected 443 responses from people 18 to 64 across Missouri and its Midwest neighbors, ten states in all, drawn from the general public, not screened patients. Some questions accepted more than one answer, so those totals top 100. Every result follows the provider's final validation; we cite top-line numbers only and state no subgroup figures.